Nephrology therapeutics and kidney disease treatments
Strategic Profile
The company is optimistic about potential approval of OLC and focused on preparations for the subsequent launch of OLC, with an FDA PDUFA target action date of June 29, 2026. Unicycive's second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. As of March 30, 2026, cash, cash equivalents, and marketable securities totaled $54.9 million, with sufficient resources to fund planned operations into 2027.
Cyborg Score Rationale
Unicycive is at an inflection point with an imminent FDA decision on its lead asset OLC (expected June 29, 2026). The company has adequate cash runway into 2027 and is preparing for potential commercial launch. However, regulatory and commercial execution risks remain material, and approval is not guaranteed.
Top Insights
June 29, 2026 PDUFA target action date represents critical near-term catalyst for OLC approval
Lead indication (hyperphosphatemia in dialysis patients) affects nearly 75% of U.S. patients with chronic kidney disease undergoing dialysis
Company faces ongoing securities litigation (class action and derivative suits filed October-November 2025) centered on fiduciary duty claims
Second program (UNI-494) has orphan drug designation for acute kidney injury prevention, potential for accelerated pathway
Named Competitors
Sevelamer — Established phosphate binder for dialysis patients